SCHEMBL3526559

SCHEMBL3526559

Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2F)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.79
FLT3 P36888 8/20 0.78
KIT P10721 6/20 0.78
AURKA O14965 5/20 0.78
LCK P06239 5/20 0.78
RET P07949 5/20 0.78
FGFR1 P11362 5/20 0.78
BLK P51451 5/20 0.78
RPS6KA3 P51812 5/20 0.78
STK3 Q13188 5/20 0.78
MAP4K5 Q9Y4K4 5/20 0.78
ROCK2 O75116 4/20 0.78
RPS6KA5 O75582 4/20 0.78
MAP4K4 O95819 4/20 0.78
LYN P07948 4/20 0.78
FLT1 P17948 4/20 0.78
RPS6KB1 P23443 4/20 0.78
AXL P30530 4/20 0.78
FRK P42685 4/20 0.78
CSNK1A1 P48729 4/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526162 0.90 KDR (0.78) KDRFLT3KITAURKALCK
SCHEMBL3530481 0.89 KDR (0.78) KDRFLT3KITAURKALCK
SCHEMBL3534175 0.89 KDR (1.00) KDRFLT3KITAURKALCK
SCHEMBL234334 0.88 KDR (1.00) KDRFLT3KITAURKALCK
SCHEMBL3528941 0.88 KDR (0.65) KDRFLT3KITAURKALCK
SCHEMBL6092809 0.86 KDR (1.00) KDRFLT3KITAURKALCK
SCHEMBL3534032 0.85 KDR (0.77) KDRFLT3KITAURKALCK
SCHEMBL3530171 0.83 KDR (0.78) KDRFLT3KITAURKALCK
SCHEMBL3530160 0.81 KDR (0.79) KDRFLT3KITAURKALCK
SCHEMBL3524840 0.80 KDR (1.00) KDRFLT3KITAURKALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed
US-20050020619-A1 Thienopyridine kinase inhibitors ABBOTT LABORATORIES 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020619-A1 Thienopyridine kinase inhibitors ABL1, MAP4K2, MAP4K5 KDR 511/4885FLT3 45/4885KIT 340/4885
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885KIT 188/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885KIT 188/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885KIT 188/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885KIT 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.